| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/13/2013 | EP2555756A2 Controlled release pharmaceutical compositions of tapentadol |
| 02/13/2013 | EP2555618A1 Methods of using diacerein as an adjunctive therapy for diabetes |
| 02/13/2013 | CN102933233A Agent for treating renal fibrosis |
| 02/13/2013 | CN102933210A Wake-time-extending agent |
| 02/13/2013 | CN102925564A Use and expression vector of gene C2orf40 in preparation of medicines for preventing, diagnosing or treating tumor of breast and diagnosis medicine thereof |
| 02/13/2013 | CN102921009A Novel niacin compound sustained release preparation for treating hyperlipidemia |
| 02/13/2013 | CN102921008A Stable drug composition containing calcium blockers |
| 02/13/2013 | CN102921007A Method and reagent used for controlling insulin resistance and diabetes mellitus |
| 02/13/2013 | CN102921003A Stabilized immune modulatory RNA (SIMRA) compounds |
| 02/13/2013 | CN102921000A Application of acetylcholinesterase as nuclease |
| 02/13/2013 | CN101926996B Application of methotrexate and ABC inhibitor to preparation of medicament for treating psoriasis |
| 02/13/2013 | CN101837128B Medicament composition containing sorafenib, MEK inhibitors and EGFR tyrosine kinase inhibitors and application thereof |
| 02/13/2013 | CN101744767B Thermal sensitive liposome preparation containing camptothecin antineoplastic agents |
| 02/13/2013 | CN101653608B Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof |
| 02/13/2013 | CN101653607B Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof |
| 02/13/2013 | CN101653606B Pharmaceutical composition containing protein kinase B inhibitor and epidermal growth factor recipient tyrosine kinase inhibitor and application thereof |
| 02/13/2013 | CN101534852B Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| 02/13/2013 | CN101439015B Pharmaceutical composition with enhanced bioavailability |
| 02/13/2013 | CN101341170B Antibodies against interleukin-22 binding protein and uses thereof |
| 02/13/2013 | CN101325973B Use of oligouronates for treating mucus hyperviscosity |
| 02/13/2013 | CN101052312B Compositions for improving oxidative status in companion animals |
| 02/12/2013 | US8372968 RNA interference mediating small RNA molecules |
| 02/12/2013 | US8372413 Mycobacterial disease, malaria, leishmaniasis, toxoplasmosis, schistosomiasis and clonorchiasis; antiallergens; asthma |
| 02/12/2013 | US8372404 Anti-C5/C5a antibodies and methods of use |
| 02/12/2013 | CA2566873C Use of drug combinations for treating insulin resistance |
| 02/12/2013 | CA2480638C Substituted benzazoles and use thereof as raf kinase inhibitors |
| 02/12/2013 | CA2445634C Acne treatment comprising lipoxygenase inhibitors |
| 02/12/2013 | CA2429817C Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| 02/12/2013 | CA2388450C Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 02/12/2013 | CA2359650C Pharmaceutical preparations and methods for inhibiting tumors |
| 02/07/2013 | WO2013019974A1 Compositions comprising a retinoid and a lincosamide antibiotic for use in treating rosacea |
| 02/07/2013 | WO2013019926A1 Treatment and prevention of diseases mediated by microorganisms via drug-mediated manipulation of the eicosanoid balance |
| 02/07/2013 | WO2013018886A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| 02/07/2013 | WO2013018883A1 Cancer treatment and/or prevention drug composition |
| 02/07/2013 | WO2013018882A1 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| 02/07/2013 | WO2013018837A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | WO2013018069A1 Combination of antimalarial agents |
| 02/07/2013 | WO2013017808A1 Antiseptic composition |
| 02/07/2013 | WO2013017807A1 Antiseptic composition |
| 02/07/2013 | WO2013017233A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/07/2013 | US20130035319 Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
| 02/07/2013 | US20130035312 Cathepsin cysteine protease inhibiors |
| 02/07/2013 | CA2848369A1 Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| 02/07/2013 | CA2844037A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
| 02/07/2013 | CA2844030A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2842906A1 Left ventricular diastolic function improving agent |
| 02/07/2013 | CA2842577A1 Antiseptic composition |
| 02/07/2013 | CA2839122A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/06/2013 | EP2554184A1 Preventive and/or remedy for hand and foot syndrome |
| 02/06/2013 | EP2554181A2 Methods of protecting against apoptosis using lipopeptides |
| 02/06/2013 | EP2554164A1 Pharmaceutical formulation based on ibuprofen and codeine having having improved stability |
| 02/06/2013 | EP2552491A1 Staining composition |
| 02/06/2013 | EP2552452A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer |
| 02/06/2013 | EP2552446A1 Method for treating schizophrenia and related diseases |
| 02/06/2013 | EP2552442A1 Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
| 02/06/2013 | EP2552436A1 Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide |
| 02/06/2013 | EP2552433A2 Compositions and methods for the treatment of somatosensory disorders |
| 02/06/2013 | EP2552431A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia |
| 02/06/2013 | EP2552430A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
| 02/06/2013 | EP2552429A1 Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
| 02/06/2013 | EP2552428A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling |
| 02/06/2013 | EP2552407A1 Composition comprising insulin and herbal oil for transdermal or transmucosal administration |
| 02/06/2013 | EP2552404A1 Parenteral pharmaceutical form which releases aromatse inhibitor and gestagens, for the treatment of endometriosis |
| 02/06/2013 | EP2552402A2 Multilayer melt-extruded film |
| 02/06/2013 | EP2552347A1 Method for stimulating the reproductive capacity in a bull, and composition for stimulating the reproductive capacity in a bull |
| 02/06/2013 | EP2552205A1 Methods of improving quality of sleep |
| 02/06/2013 | CN102917733A Selection and use of host cells for production of glycoproteins |
| 02/06/2013 | CN102917701A Use of riluzole to treat or prevent the adverse effects of antineoplastic agents |
| 02/06/2013 | CN102908629A Lipid-based drug of serum degradable carrier and application method of lipid-based drug |
| 02/06/2013 | CN102908624A Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist |
| 02/06/2013 | CN102908623A Formulas comprising highly soluble elements and vitamin D3 for the prevention and amelioration of osteoporosis |
| 02/06/2013 | CN102908622A Application of 5-LO (lipoxygenase) inhibitor for treatment of malignant tumor in blood system |
| 02/06/2013 | CN102908621A New application of miRNAs for regulating insulin sensitivity as target |
| 02/06/2013 | CN102908351A Dipeptidyl peptidase inhibitors for treating diabetes |
| 02/06/2013 | CN102908350A Dipeptidyl peptidase inhibitors for treating diabetes |
| 02/06/2013 | CN102908346A Use of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
| 02/06/2013 | CN102908339A Tapentadol compositions |
| 02/06/2013 | CN102908308A Pharmaceutical solution formulations for pressurised metered dose inhalers |
| 02/06/2013 | CN101743001B Combination anticoagulant therapy with a compound that acts as a factor XA inhibitor |
| 02/06/2013 | CN101583366B Radiation sensitizer or anti-cancer chemotherapy sensitizer |
| 02/05/2013 | US8367733 Composition for attenuation of pain or wound healing agents in dosage |
| 02/05/2013 | US8367646 Steroid compounds and treatment methods |
| 02/05/2013 | US8367644 Methods and compounds useful to induce apoptosis in cancer cells |
| 02/05/2013 | US8367070 Modified surface antigen |
| 02/05/2013 | US8367052 Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies |
| 02/05/2013 | CA2555099C Alcohol metabolism moderating composition |
| 02/05/2013 | CA2479555C Use of cocoa flavanols and oligomers thereof to treat cognitive dysfunction and improve cognitive function in neuro-compromised patients |
| 02/05/2013 | CA2464277C Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| 02/05/2013 | CA2428176C Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2013 | CA2420867C Methods for enhancing the efficacy of cancer therapy |
| 01/31/2013 | WO2013015388A1 Ndm inhibitor |
| 01/31/2013 | WO2013014497A1 Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | WO2013014496A1 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | US20130030005 Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives with protease inhibitors |
| 01/31/2013 | US20130028911 Vascular endothelial cell growth factor antagonists |
| 01/31/2013 | US20130028910 Hmg1 antibody for treating inflammatory conditions |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | DE102011108948A1 Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen Aqueous colloidal solutions of lipophilic substances, particularly drug solutions |
| 01/31/2013 | CA2842779A1 Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| 01/31/2013 | CA2842777A1 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |